Reuters

HEALTH

Alzheimer's drug adoption in US slowed by doctors' skepticism

  • Leqembi, the first drug proven to slow Alzheimer's, faces an unexpected hurdle nine months after its US launch
  • Its broad use is slowed by an entrenched belief among some doctors that treating the memory-robbing disease is futile
  • In interviews with Reuters, seven doctors attributed their own reluctance to concerns about efficacy, cost and risks
Showcase
For youTop storiesLocalFollowing
Search
Clear search
Close search
Google apps
Main menu